IGAP - IGAP STOCK NEWS

Integrity Applications, Inc. (NASDAQ: IGAP) has provided a shareholder update focusing on advancements in its non-invasive glucose monitoring device, GlucoTrack. Paul V. Goode has been appointed as CEO, highlighting his commitment to bringing innovative diabetes management solutions to market. A successful uplisting to Nasdaq was completed, enhancing corporate visibility and providing a $100 million shelf registration for future growth. The new GlucoTrack 2.0 device will be fully wireless and is in rapid development, aiming for clinical trials in Q2 2022.

Integrity Applications, Inc. (NASDAQ: IGAP) has appointed Paul V. Goode, PhD, as CEO following a strategic board shift. The company has successfully uplisted to Nasdaq as part of a broader corporate restructuring aimed at enhancing visibility and liquidity. GlucoTrack, a non-invasive glucose monitoring device, is set to progress with the next-generation GlucoTrack 2.0 featuring improved wireless technology and sensing capabilities. A $100 million shelf registration provides financial flexibility. The company emphasizes strong fiscal management and talent acquisition to drive future growth.

Integrity Applications, Inc. (OTCQB: IGAP) announced that its common stock has been approved for listing on the Nasdaq Capital Market, with trading expected to begin on December 10, 2021. This uplisting marks a significant milestone for the company and its shareholders, enhancing visibility and liquidity. The company plans to change its name to GlucoTrack, Inc. shortly after the uplisting. GlucoTrack® is a non-invasive device designed to measure glucose levels quickly and painlessly in individuals with Type 2 diabetes and prediabetes.

Integrity Applications, Inc. (OTCQB: IGAP) announced the appointment of James P. Thrower, PhD, as Vice President of Engineering. He brings over 15 years of medical device experience, with a focus on product development and regulatory processes. Thrower previously worked at Sterling Medical Devices and held leadership roles at companies like Mindray and DexCom. His expertise will support the commercial launch of the non-invasive glucose monitoring device, GlucoTrack®, designed for Type 2 diabetes and prediabetes patients.

Integrity Applications, Inc. (OTCQB: IGAP) has announced its corporate name change to GlucoTrack, Inc., effective upon FINRA approval, expected around December 3, 2021. This decision aligns the company’s identity with its flagship product, the GlucoTrack non-invasive glucose monitoring device. The change follows stockholder approval at the Annual Meeting on March 24, 2020. GlucoTrack is designed for rapid, painless glucose level measurement and aims to improve branding and visibility in the diabetes market.

Integrity Applications, Inc. (OTCQB: IGAP) has appointed Paul V. Goode as President and Chief Operating Officer, effective November 1, 2021. Goode, a board member since December 2020, will also lead operations, strategy, and U.S. infrastructure for upcoming clinical trials of the GlucoTrack® device. With over 20 years in medical device innovation, Goode has significant experience in diabetes management technologies. The company aims to enhance the GlucoTrack® platform to improve diabetes care, continuing their mission to innovate non-invasive glucose monitoring solutions.

Integrity Applications, Inc. (OTCQB: IGAP) has filed a universal shelf registration statement with the SEC, potentially allowing it to offer up to $100 million in securities, including common stock and debt securities. The purpose of this filing is to facilitate timely access to capital markets, though no specific plans for offerings are currently in place. GlucoTrack^®, a non-invasive glucose monitoring device developed by the company, measures glucose levels without finger pricking and has received regulatory approvals in Europe and South Korea.

Integrity Applications, Inc. (OTCQB: IGAP) has announced a 1-for-13 reverse stock split effective on August 13, 2021. This move, approved by stockholders in March 2020, aims to meet the $4.00 minimum price requirement for NASDAQ uplisting. The split will reduce outstanding shares from approximately 200.8 million to about 15.4 million, with no change to ownership percentages or voting power. The stock will trade as "IGAPD" initially, then revert to "IGAP" after 20 business days.

Integrity Applications, Inc. (OTCQB: IGAP) has appointed Luis J. Malavé to its Board of Directors, effective immediately. Malavé, with over 30 years of experience in the MedTech industry, particularly in diabetes management, is expected to enhance the company's strategic direction. His previous leadership roles include President of EOFLOW CO. Ltd. and CEO of Palyon Medical. The company's GlucoTrack® device, a non-invasive glucose monitoring system, is aimed at the diabetes market and has received regulatory approvals in Europe and South Korea.